Disclosed are short DNA aptamers that selectively recognize CD200R1, a protein expressed on the surface of myeloid and lymphoid cells that delivers immune inhibitory signals to modulate inflammation when engaged with its ligand, CD200. Also disclosed is the use of said aptamers as therapeutic agents, for the purpose of decreasing inflammatory response treatment of spinal cord injury treatment of an immune related disease such as arthritis, allergy, infection as a course of treatment during or after transplantation or for treatment of an autoimmune disorders such as systemic lupus erythematosus, Parkinsons Disease, or multiple sclerosis.
